Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS

(HIK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Hikma Announces Tie-Up With Vectura; Raises Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2018 | 03:12am EDT

By Carlo Martuscelli

Hikma Pharmaceuticals announced Thursday a tie-up with inhaler producer Vectura Group to collaborate on the development of generic versions of GlaxoSmithKline Ellipta drugs.

Hikma also raised its guidance on the back of a strong performance in its injectables division. The generic drug manufacturer said it now sees revenue from the medicine group in the range of $825 million to $850 million, with a core injectables operating margin of between 39%gene and 40%.

The company said Vectura's inhaler technology has the potential to be developed into a generic version of the Ellipta portfolio--a group of drugs for the treatment of chronic obstructive pulmonary disease and asthma. The deal includes the development of at least three drugs in the portfolio, with first priority going to developing a generic version of Breo Ellipta.

Under the terms of the deal Hikma will make an upfront payment of $15 million to Vectura. Vectura will develop the device and formulation, while Hikma will be responsible for clinical development, the regulatory process and commercialization, Hikma said.

Once the first product is delivered to the company's facilities to enable clinical manufacturing, Hikma will make a $5 million payment to Vectura followed by milestone payments of up to $75 million at various stages of development.

Once the products are developed Hikma said it will pay net profit up to a mid-teen percentage for each product, plus sales milestone payments. Vectura in turn will pay up to $70 million for development activities, Hikma said.

The company noted the generic respiratory market is a key area of focus for the company and said its injectables division continues to perform ahead of expectations.

"While the US retail market remains challenging, with continued price erosion, the recent commercial and operational improvements we have made to our business are enabling us to deliver strong growth from our more differentiated portfolio," it said.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 1.42% 17.986 Delayed Quote.6.64%
GLAXOSMITHKLINE 0.68% 1550.8 Delayed Quote.3.30%
HIKMA PHARMACEUTICALS -1.03% 1676 Delayed Quote.-1.31%
VECTURA GROUP PLC 0.69% 73 Delayed Quote.3.57%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
04/15HIKMA PHARMACEUTICALS : Annual Financial Report
PU
04/09HIKMA PHARMACEUTICALS : Participates in 'World Economic Forum on the Middle East..
AQ
04/04HIKMA PHARMACEUTICALS : Ex-dividend day for final dividend
FA
04/03HIKMA PHARMACEUTICALS : Block listing Interim Review
AQ
03/25HIKMA PHARMACEUTICALS : launches Norepinephrine Bitartrate Injection, USP
AQ
03/19LONDON STOCK EXCHANGE : FTSE 100 in seventh heaven as oil, miners gain; Ocado hi..
RE
03/19HIKMA PHARMACEUTICALS : Director/PDMR Shareholding
AQ
03/17HIKMA PHARMACEUTICALS : Director/PDMR Shareholding
AQ
03/15HIKMA PHARMACEUTICALS : Director/PDMR Shareholding
AQ
03/14HIKMA PHARMACEUTICALS : delivers strong 2018 results and makes good strategic pr..
AQ
More news
Financials ($)
Sales 2019 2 125 M
EBIT 2019 459 M
Net income 2019 299 M
Debt 2019 160 M
Yield 2019 1,74%
P/E ratio 2019 18,08
P/E ratio 2020 16,45
EV / Sales 2019 2,59x
EV / Sales 2020 2,44x
Capitalization 5 347 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 25,0 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS-1.31%5 347
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697